Thus, a non-invasive urine test using PCa-specific biomarkers is independent of biopsy tissue or PSA and may provide more accurate risk assessment for treatment decision and more convenient periodic monitoring for cancer surveillance. This evidence concerns the gene KLK3 and posterior cortical atrophy.